key: cord-0939990-otc87wy7
authors: Parvathy, Seema Nair; Lenehan, John G; Fernandes, Ricardo; Poutanen, Susan M; Hota, Susy; Maleki Vareki, Saman; Silverman, Michael
title: Enhanced donor screening for faecal microbial transplantation during COVID-19
date: 2021-03-31
journal: Gut
DOI: 10.1136/gutjnl-2021-324593
sha: 7a55088ea5876b073030f6a29226f93bfe655199
doc_id: 939990
cord_uid: otc87wy7

nan

PostScript high-risk procedure 5 due to aerosolisation and contact with infected bodily fluids (sputum, faecal matter and even bile 6 ), but linking transmission of SARS-CoV-2 to a previous endoscopic procedure is difficult, considering the large variation in both the incubation and viraemic periods.

The authors did not account for the timing of endoscopy in relation to the moment of infection and/or admission. As shown by recent studies, viral load in patients with COVID-19 decreases substantially over a short period of time, 7 so even patients in critical condition might, in fact, have low viral loads when admitted to the endoscopy ward. Moreover, there is evidence that supports a rapid decline in infectivity after several days, 8 independent of viral load, 9 possibly justifying the lack of infectious isolates from the collected samples. In our own experience, there have been significant delays in access to endoscopy for patients with COVID-19 (data currently under review for publication), and this might, at least in part, account for the results of Boškoski et al. The findings of the study are reassuring, and we would like to point out that, even positive PCR findings would still not be enough to confirm infectivity since viral viability should be demonstrated by means of culture rather than PCR.

Due to the significant impact of the SARS-CoV-2 on patient care, in-depth studies to establish clear correlations between viral load, infectivity and transmission risks are required to provide definitive answers in this matter.

We read with interest the recent article by Ianiro et al 1 which is a guidance document on faecal microbial transplantation (FMT) during the COVID-19 pandemic. This guidance document advocated stool testing for SARS-CoV-2 and nasopharyngeal sampling was recommended. The pandemic has imposed new challenges to healthcare systems around the world. Since SARS-CoV-2 RNA can be found in the stool of infected individuals, 2 this has raised safety concerns for administering FMTs. The US Food and Drug Administration has recommended that only FMT products generated from stools donated before 1 December 2019 should be used until further guidance on SARS-CoV-2 testing protocols are available. 3 However, the supply of prestored samples has dwindled and the stability of the microbes and the efficacy of FMT after prolonged storage are questionable. 4 Currently many FMT centres are closed with no available FMT treatment for recurrent Clostridioides difficile Infection (rCDI) or other patients. We aim to share our Health Canada-approved strategy in performing FMTs during the pandemic in our rCDI clinic and our ongoing oncology clinical trials with the hope that more centres can safely restart their FMT programmes. We will focus on the three-stage FMT donor screening pertaining to COVID-19 as other components of the programme remain the same. 5 Donors are administered a questionnaire, over the phone, before each sample drop-off. The screening questionnaire includes COVID-19 symptoms, whether they have previously tested positive for COVID-19, have travelled outside of Canada in the last 14 days, had close unprotected contact with a confirmed case of COVID-19 or worked in any facility with a declared COVID-19 outbreak. If the answer is yes to any of these questions, then they are excluded and referred for SARS-CoV-2 testing (figure 1). If testing is negative and they become asymptomatic, they are eligible for rescreening after 14 days. If the donors passed the questionnaire, they would visit the clinic and drop off their stool samples. During each visit donors provide a nasopharyngeal swab for COVID-19 testing (reverse transcription Polymerase chain reaction (RT PCR) and a portion of the stool sample is tested for SARS-CoV-2 RT PCR. 6 Stool donations are then processed and quarantined (−80°C) until PCR results are available. Donors are advised to quarantine if there is a positive result and the Ontario Public Health is notified and stool samples disposed of following a biological hazard protocol. Stool samples are processed into capsules. 7 We chose FMT delivery via capsules as the preferred method as it is non-invasive and does not generate aerosols. Enema is administered to patients unable to swallow capsules, with staff wearing gowns, surgical masks, gloves and face shield in a dedicated room. All patients are followed up by telephone for 30 days post-FMT. All donors and PostScript recipients provide written informed consent.

We have administered FMTs to 35 patients (9 enemas and 26 by capsules) starting August 2020 with no cases of COVID-19 reported in the recipients following FMT (figure 1). No donors tested positive for SARS-CoV-2. No donors or recipients have yet been vaccinated for COVID-19. We will continue the same protocol irrespective of donor or recipient vaccination status. Ianiro et al 8 have also published their experience on maintaining the FMT service during the pandemic. 8 To our knowledge this is the largest cohort of patients undergoing FMT reported since the onset of the pandemic and the first reported to include stool SARS-CoV-2 testing. Our data demonstrate that FMT can be safely performed despite pandemic restrictions. 

Endoscopes used in positive and critically ill patients are SARS-CoV-2 negative at virological assessment

ASGE guideline for infection control during GI endoscopy

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Low risk of SARS-CoV-2 transmission by fomites in real-life conditions

Extent of infectious SARS-CoV-2 aerosolisation as a result of oesophagogastroduodenoscopy or colonoscopy

SARS-CoV-2 in the bile of a patient with COVID-19-associated gallbladder disease

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Temporal dynamics in viral shedding and transmissibility of COVID-19

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

Fecal viral shedding in COVID-19 patients: clinical significance, viral load dynamics and survival analysis

Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19

What are the optimal long-term storage conditions for donor samples used in fecal microbiota transplantation

Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases

Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification

Effect of oral Capsule-vs Colonoscopy-Delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial

Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: a prospective cohort study

Competing interests None declared.

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Ethics approval Study was approved by the Research Ethics Board of Western University.Provenance and peer review Not commissioned; externally peer reviewed.

Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See